X0206 3 2015-06-24 0 0001454789 CATABASIS PHARMACEUTICALS INC CATB 0001394939 Jirousek Michael C/O CATABASIS PHARMACEUTICALS, INC. ONE KENDALL SQUARE BLDG. 1400E, SUITE B14202 CAMBRIDGE MA 02139 0 1 0 0 Chief Scientific Officer Common Stock 179026 D Series A Preferred Stock Common Stock 66658 D Series B Preferred Stock Common Stock 409 D Common Stock Warrant (right to buy) 1.67 2019-10-31 Common Stock 7504 D Common Stock Warrant (right to buy) 1.67 2019-10-31 Common Stock 833 D Common Stock Warrant (right to buy) 1.67 2019-10-31 Common Stock 416 D Stock Option (right to buy) 1.67 2021-02-28 Common Stock 84276 D Stock Option (right to buy) 2.31 2022-12-17 Common Stock 22292 D Stock Option (right to buy) 2.31 2022-12-17 Common Stock 32477 D Stock Option (right to buy) 2.31 2023-04-16 Common Stock 28605 D Stock Option (right to buy) 6.81 2024-03-18 Common Stock 31128 D Stock Option (right to buy) 11.05 2025-03-25 Common Stock 8171 D Reflects a 1-for-12.85 reverse stock split effected on June 11, 2015. The Series A Preferred Stock is convertible into Common Stock on a 1-for-12.85 basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. The Series B Preferred Stock is convertible into Common Stock on a 1-for-12.85 basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Immediately. This option was granted on December 18, 2012 and vested as to 25% of the shares on December 1, 2012 with the remaining 75% of the shares vesting in equal monthly installments thereafter through December 1, 2015. This option was granted on December 18, 2012 and vested as to 25% of the shares on July 10, 2013 with the remaining 75% of the shares vesting in equal monthly installments thereafter through July 10, 2016. This option was granted on April 17, 2013 and vested as to 25% of the shares on January 18, 2014 with the remaining 75% of the shares vesting in equal monthly installments thereafter through January 18, 2017. This option was granted on March 19, 2014 and vested as to 25% of the shares on January 1, 2015 with the remaining 75% of the shares vesting in equal monthly installments thereafter through January 1, 2018. This option was granted on March 26, 2015 and vests over four years with 25% of the shares vesting on March 26, 2016, and the remaining 75% of the shares vesting in equal monthly installments thereafter through March 26, 2019. Exhibit Index: 24.1 Power of Attorney /s/ Michael Jirousek 2015-06-24